华森制药(002907) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥238,944,153.42, representing a 4.62% increase compared to ¥228,392,771.39 in the same period last year[5]. - Net profit attributable to shareholders was ¥40,355,212.38, showing a slight increase of 0.01% from ¥40,351,252.07 year-on-year[5]. - Total revenue for the current period reached ¥238,944,153.42, an increase of 4.8% compared to ¥228,392,771.39 in the previous period[23]. - Net profit for the current period was ¥40,355,212.38, slightly up from ¥40,351,252.07 in the previous period, indicating a stable performance[24]. - The company's total assets increased to ¥1,953,562,392.47 from ¥1,917,549,589.00, representing a growth of 1.9%[22]. - The total liabilities decreased to ¥253,065,305.37 from ¥257,551,310.62, a reduction of 1.9%[22]. - The retained earnings rose to ¥721,986,844.70 from ¥681,631,632.32, marking an increase of 5.9%[22]. - Basic and diluted earnings per share remained stable at ¥0.0966 for both periods[24]. Cash Flow - The net cash flow from operating activities increased significantly by 146.83%, reaching ¥21,860,943.05, primarily due to an increase in the settlement of acceptance bills[5]. - Operating cash flow for the current period is ¥21,860,943.05, a significant increase of 147.5% compared to ¥8,856,696.04 in the previous period[25]. - Total cash inflow from operating activities is ¥191,675,253.51, up from ¥169,841,410.14, reflecting a growth of 12.3%[25]. - Cash outflow from operating activities increased to ¥169,814,310.46 from ¥160,984,714.10, representing a rise of 5.1%[25]. - The company reported a cash outflow of ¥28,800.00 from financing activities, an improvement from a cash outflow of ¥100,200.00 in the previous period[26]. - The impact of exchange rate changes on cash and cash equivalents was a negative ¥136,374.95, contrasting with a positive impact of ¥7,308.33 previously[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,953,562,392.47, up 1.88% from ¥1,917,549,589.00 at the end of the previous year[5]. - The total current assets at the end of the period amounted to ¥1,091,355,563.01, an increase from ¥1,031,344,511.28 at the beginning of the period[20]. - The company has a long-term equity investment of ¥14,188,853.36, down from ¥15,414,034.45 at the beginning of the period[20]. - The company's inventory decreased to ¥127,823,788.51 from ¥140,125,411.63 at the beginning of the period[20]. - The company reported a decrease in contract liabilities from ¥8,688,989.46 to ¥4,550,742.76, a decline of 47.7%[22]. Market Performance - Sales of the key product, Ganqi Bingmei Tablets, experienced a decline due to reduced market demand, while other key traditional Chinese medicines showed growth, with Liuwu Anshen Capsules increasing by 32.10% and Tongxiening Granules by 80.24%[9]. - The overall growth of national drug collection varieties was 28.71%, indicating strong market access and execution capabilities[9]. Other Financial Metrics - The company's weighted average return on equity decreased to 2.40% from 2.46% year-on-year[5]. - Other income decreased by 34.98% to ¥2,348,546.56, primarily due to a reduction in government subsidies received[11]. - The company reported a credit impairment loss of ¥2,014,007.51, a decrease of 30.76% compared to the previous year, attributed to enhanced collection efforts[12]. - Research and development expenses were ¥12,304,890.58, slightly down from ¥12,644,702.28, indicating a focus on cost management[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,712[15]. - The largest shareholder, Chengdu Local Construction Machinery Engineering Co., Ltd., holds 42.04% of the shares[15]. - The total number of preferred shareholders at the end of the reporting period is not applicable[18]. Investment Activities - The net cash flow from investing activities decreased significantly by 4961.47% to -¥181,171,345.21, mainly due to an increase in the purchase of financial products[16]. - Total cash outflow for investment activities was ¥302,374,756.73, significantly higher than ¥3,579,423.53 in the previous period[25]. - The company received ¥120,000,000.00 from investment recoveries during the current period, with no such inflow reported in the previous period[25].